The Biomarkers of Aging Consortium will convene its fourth annual conference at Harvard Medical School in October 2026, assembling researchers, clinicians, industry developers, regulators, and funders around the validation of aging biomarkers. The central problem addressed is standardization: therapies targeting aging are nearing clinical testing, but the field lacks agreed-upon methods to confirm that an intervention has altered biological aging. Satellite programs extend the agenda into brain aging, reproductive aging, and replacement-based regenerative strategies.
Key Points
- Fourth annual aging biomarker conference convenes at Harvard, October 2026
- Focus: validating biomarkers as trial endpoints regulators accept
- Satellite sessions cover brain aging, reproductive aging, regenerative replacement
Longevity Analysis
Measurement precedes intervention. Without validated markers that track the pace of aging across immune function, tissue renewal, and metabolic capacity, clinical decisions and trial endpoints rest on proxies rather than biology. Bringing epigenetic clock developers, multi-omic profilers, and regulatory scientists into the same forum moves the field toward signals that can be interpreted consistently — the precondition for knowing whether any longevity protocol is working rather than merely being followed.
Original published by LifeSpan.io, by Press release.